MedTrace Logo

A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease

NCT01122329 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2015-03-23

No results posted yet for this study

Summary

This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

caprylidene

Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

Principal Investigators

  • Joshua Grill, PhD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

  • John Ringman, MD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

  • Maryam Beigi, MD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

  • Ellen Woo, PhD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

  • Dan Silverman, MD, PhD · UCLA Department of Molecular and Medical Pharmacology

  • Cathy Lee, PhD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

  • Jeffrey Cummings, MD · Mary S. Easton Center for Alzheimer's Disease Research at UCLA

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122329 on ClinicalTrials.gov